
GMDAQ
Healthcare · Biotechnology
Latest report
After the close
The next earnings date isn’t on the calendar yet.
Analyst consensus
Analyst estimates aren’t available for this symbol.
Beat estimates in 1 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| May 23, 2024 | After the close | -0.13 | -0.13 | 0.0% |
| Mar 27, 2024 | Before the open | -0.15 | -0.04 | +73.3% |
| Nov 14, 2023 | Time not confirmed | — | -0.01 | — |
| Aug 14, 2023 | Time not confirmed | — | -0.31 | — |
| May 16, 2023 | Time not confirmed | — | -0.27 | — |
| Mar 27, 2023 | Time not confirmed | — | -0.31 | — |
| Nov 14, 2022 | Time not confirmed | — | -0.29 | — |
| Aug 15, 2022 | Time not confirmed | — | -0.31 | — |
| May 10, 2022 | Time not confirmed | — | -0.34 | — |
| Nov 15, 2021 | Time not confirmed | — | -0.33 | — |
| Aug 11, 2021 | Time not confirmed | — | -0.36 | — |
| May 11, 2021 | Time not confirmed | — | -0.30 | — |
| Mar 9, 2021 | Time not confirmed | — | -0.55 | — |
| Nov 10, 2020 |
Gamida Cell Ltd. researches, develops, and commercializes cell therapies. The company offers Omisirge (omidubicel-onlv), a cell therapy for use in treatment of patients with hematologic malignancies and severe aplastic anemia. Its product candidate includes GDA-201, an investigational NK cell-based cancer immunotherapy, for the treatment of hematologic and solid tumors, as well as to treat follicular and diffuse…
| Time not confirmed |
| — |
| -0.30 |
| — |
| Aug 11, 2020 | Time not confirmed | — | -0.30 | — |
| May 21, 2020 | Time not confirmed | — | -0.31 | — |
| Feb 25, 2020 | Time not confirmed | — | -0.44 | — |
| Nov 14, 2019 | Time not confirmed | — | -0.30 | — |
| Aug 6, 2019 | Time not confirmed | — | -0.44 | — |
| May 7, 2019 | Time not confirmed | — | -0.62 | — |